Modality
Vaccine
MOA
CDK2i
Target
CDK2
Pathway
Incretin
MS
Development Pipeline
Preclinical
May 2024
→ Nov 2030
PreclinicalCurrent
NCT03182500
2,387 pts·MS
2024-05→2030-11·Terminated
2,387 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-134.6y awayInterim· MS
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2030-11-13 · 4.6y away
MS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03182500 | Preclinical | MS | Terminated | 2387 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 |